Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2012
11/01/2012WO2012146110A1 Insulin-delivering transdermal formulation and preparation method therefor
11/01/2012WO2012146052A1 Risperidone sustained release microsphere composition
11/01/2012WO2012145893A1 A composition of entacopone
11/01/2012WO2012145801A1 Nanoparticle
11/01/2012WO2012121528A3 Magnetic nanocomposite specific for thyroid cancer and use thereof
11/01/2012WO2012111965A3 Orally administered sustained-release triple-layer pill containing tamsulosin or pharmaceutically acceptable salt thereof
11/01/2012WO2012110971A3 Method and composition to retard sorption of preservatives to plastics
11/01/2012WO2012108648A3 Method of preparing iron oxide nanoparticles coated with hydrophilic material, and magnetic resonance imaging contrast agent using the same
11/01/2012WO2012094574A3 Stabilized polyribonucleotide nanoparticles
11/01/2012WO2012092510A3 Ocular drug delivery system
11/01/2012WO2012092486A3 Modified release benzimidazole formulations
11/01/2012WO2012092305A3 Nanonized iron compositions and methods of use thereof
11/01/2012WO2012090150A3 New cell-penetrating peptides and uses thereof
11/01/2012WO2012090070A3 Biodegradable drug delivery compositions
11/01/2012WO2012085847A3 Triggered polymer viscous pill and methods of using the same
11/01/2012WO2012083138A3 Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
11/01/2012WO2012066581A4 Novel conjugates for targeted drug delivery
11/01/2012WO2012063257A9 Sustained release compositions
11/01/2012WO2012054408A3 Bioavailability enhancement delivery system
11/01/2012US20120277695 Transdermal delivery patch
11/01/2012US20120277324 Betaine esters and process for making and using
11/01/2012US20120277323 Cellulose capsules and methods for making them
11/01/2012US20120277321 Method for preparing a composition comprising a compound based on vanillin and ethyl vanillin, resulting composition and uses thereof
11/01/2012US20120277315 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
11/01/2012US20120277289 Activity generating delivery molecules
11/01/2012US20120277235 Compositions For Topical Application Having Androgenic Actions
11/01/2012US20120277195 Permeation enhancers for topical formulations
11/01/2012US20120277152 Compressed high density fibrous polymers suitable for implant
11/01/2012US20120276206 Method for manufacturing acid pellets
11/01/2012US20120276191 Treatment and Diagnosis of Macrophage Mediated Disease
11/01/2012US20120276185 Soluble coating comprising polyelectrolyte with hydrophobic counterions
11/01/2012US20120276182 Methods of treating fungal, yeast and mold infections
11/01/2012US20120276180 Active Agent Delivery and/or Odor Retentive Composition and Methods of Use Thereof
11/01/2012US20120276170 Injectable drug carrier comprising layered double hydroxide
11/01/2012US20120276164 Implantable paste and its use
11/01/2012US20120276162 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
11/01/2012US20120276159 Tolerogenic synthetic nanocarriers
11/01/2012US20120276152 Systems and methods of using zinc-chelator to treat myocardial infarction
11/01/2012US20120276116 Prevention and Treatment of Amyloidogenic Disease
11/01/2012US20120276026 Volatile Cyclic Siloxanes
11/01/2012US20120275998 Biodegradable stent comprising an acid scavenging agent
11/01/2012US20120273586 Plasticized Elastomer Including a Volatile Compound
11/01/2012CA2834626A1 Therapeutic nuclease compositions and methods
11/01/2012CA2834619A1 Controlled release of immunosuppressants from synthetic nanocarriers
11/01/2012CA2834571A1 Tolerogenic synthetic nanocarriers for inducing regulatory b cells
11/01/2012CA2834534A1 Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells
11/01/2012CA2834532A1 Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
11/01/2012CA2834527A1 Tolerogenic synthetic nanocarriers to reduce antibody responses
11/01/2012CA2834519A1 Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
11/01/2012CA2834514A1 Tolerogenic synthetic nanocarriers
11/01/2012CA2834365A1 Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
11/01/2012CA2834262A1 Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
11/01/2012CA2834200A1 A method for manufacturing pegylated oligonucleotides
11/01/2012CA2834028A1 Stable pharmaceutical composition
11/01/2012CA2833500A1 Lyophilized preparation of cytotoxic dipeptides
11/01/2012CA2833443A1 A composition of entacopone
11/01/2012CA2833385A1 Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
11/01/2012CA2833115A1 Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
11/01/2012CA2832663A1 Risperidone sustained release microsphere composition
11/01/2012CA2831008A1 Novel immunoconjugates
11/01/2012CA2827952A1 Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
10/2012
10/31/2012EP2518098A1 Multi-arm polyethylene glycol derivatives, conjugates and gels of drugs and the same
10/31/2012EP2518078A1 Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
10/31/2012EP2518040A1 Low-viscosity liquid-crystal compound
10/31/2012EP2517730A2 Vitamin receptor binding drug delivery conjugates
10/31/2012EP2517729A2 Vitamin receptor binding drug delivery conjugates
10/31/2012EP2517727A2 Biomarkers for multiple sclerosis and methods of use thereof
10/31/2012EP2517712A1 Composition for improving melasma and composition for reducing skin dullness
10/31/2012EP2517710A1 Tamper-resistant oral opioid agonist formulations
10/31/2012EP2516508A2 Amphiphilic polymer functionalised by methionine
10/31/2012EP2516473A1 Anionic polysaccharides functionalised by a hydrophobic acid derivative
10/31/2012EP2516462A1 Immuno-conjugates and methods for producing them 2
10/31/2012EP2516011A1 Carrier composition
10/31/2012EP2516010A2 Lipids, lipid compositions, and methods of using them
10/31/2012EP2515946A2 Nanoconjugates and nanoconjugate formulations
10/31/2012EP2515945A1 Conjugate with target-finding ligand and use thereof
10/31/2012EP2515944A1 Methods and compositions related to annexin 1-binding compounds
10/31/2012EP2515943A2 Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients
10/31/2012EP2515942A2 Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
10/31/2012EP2515941A1 Antibody formulation
10/31/2012EP2515926A1 Compositions and methods for the treatment of angiogenesis-related eye diseases
10/31/2012EP2515909A2 Fast dissolving pharmaceutical composition comprising lornoxicam
10/31/2012EP2515897A1 A combination for the treatment of osteoarthritis
10/31/2012EP2515883A1 Abt-263 capsule
10/31/2012EP2515879A2 Fine particle croscarmellose and uses thereof
10/31/2012EP2515870A2 Topical ophthalmic peptide formulation
10/31/2012EP2515869A2 Wound care products
10/31/2012EP2515867A2 Cell tissue gel containing collagen and hyaluronan
10/31/2012EP2515866A2 Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
10/31/2012EP2515865A2 Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
10/31/2012EP2515650A1 Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
10/31/2012EP2515647A1 Pheromone compositions and methods of use
10/31/2012CN102762715A Scaffolds formed from polymer-protein conjugates, methods of generating same and uses thereof
10/31/2012CN102762647A Cross-linked oxidated hyaluronic acid for use as a vitreous substitute
10/31/2012CN102762528A Low-Viscosity Liquid-Crystal Compound
10/31/2012CN102762219A Oral care compositions
10/31/2012CN102762205A Coated solid preparation
10/31/2012CN102762195A Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
10/31/2012CN102757945A Human urate oxidase protein and preparation method and polyethylene glycol composite thereof
10/31/2012CN102757626A Preparation method of chitosan and polylactic acid composite material
1 ... 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 ... 1712